Treating HIV Infection in the Central Nervous System.
Andrea CalcagnoG Di PerriS BonoraPublished in: Drugs (2017)
Combination antiretroviral treatment is associated with clear benefits in HIV-positive subjects, and is also effective in the central nervous system (CNS), meaning HIV-associated dementia is now an uncommon event. Nevertheless, a significant number of patients show symptoms of neurocognitive impairment which may negatively affect their quality of life. Although several risk factors for HIV-associated neurocognitive disorders have been identified, there is no clear recommendation for their prevention and management. In this review, the penetration of drugs into the cerebrospinal fluid/CNS is discussed as well as the viral and clinical consequences associated with higher/lower compartmental exposure. We also review the potential interventions according to the currently identified underlying mechanisms, including persistent CNS immune activation, legacy effects, low-level viral replication and escape, co-morbidities, and antiretroviral-associated direct and indirect 'neurotoxicity'. Adjunctive therapies and interventions (including neuro-rehabilitation) are then briefly discussed. The treatment of HIV infection in the CNS is a complex area of therapeutics requiring multidisciplinary interventions and further study.
Keyphrases
- hiv positive
- antiretroviral therapy
- hiv infected
- human immunodeficiency virus
- men who have sex with men
- hiv aids
- hiv infected patients
- cerebrospinal fluid
- south africa
- hiv testing
- blood brain barrier
- physical activity
- sars cov
- newly diagnosed
- hepatitis c virus
- mild cognitive impairment
- ejection fraction
- end stage renal disease
- small molecule
- chronic kidney disease
- combination therapy